Roivant's brepocitinib beats placebo in two Phase 3 uveitis trials and heads for a US filing

Priovant Therapeutics, the Roivant subsidiary set up with Pfizer, reported on 21 October 2026 that its anti-inflammatory drug brepocitinib succeeded in two Phase 3 trials in non-infectious uveitis, an eye disease that can cause blindness¹. Priovant intends to file a supplemental application with the FDA in the first half of next year¹.

What the trials found

The two studies are called Clarity-1 and Clarity-2¹. Their main measure was time to “treatment failure”, which combines eye inflammation with other markers¹. Patients on brepocitinib went a median of more than 48 weeks before reaching that point, against 12 weeks for patients given placebo¹. Those on the drug also went 40 weeks without immunosuppressive steroids, and brepocitinib met every secondary endpoint, including the resolution of macular oedema, according to the company¹.

Priovant chief executive Ben Zimmer said the data suggest the drug could become a new standard of care in the condition¹. Quan Dong Nguyen, a Stanford professor and president of the International Ocular Inflammation Society, was quoted in the company statement: “This is the kind of outcome that can redefine expectations for an entire field”¹.

What it means for the market

Brepocitinib is already on the US market. The FDA cleared it in late August under the brand name Lisraya for adults with dermatomyositis, a skin disease¹. A second indication in uveitis would widen a franchise that began as a drug Pfizer handed over in 2022, when it took a 25% stake in the newly formed Priovant¹. Phase 2 success in uveitis followed in 2024¹.

The obvious competitor is AbbVie's Humira. The trials hint that brepocitinib may outperform it, but the two drugs were never tested against each other, so any comparison is indirect¹. Analysts are already putting numbers on the opportunity. Stifel's Alex Thompson called brepocitinib a potential “best-in-disease” medicine and wrote that the data were “further validation of the potential for brepocitinib to carve out a broader multi-indication franchise across rare/specialty markets”¹. Prakhar Agrawal of Cantor Fitzgerald estimated that non-infectious uveitis could be worth $5 billion in peak sales for the drug¹.

For Roivant the readout adds to a run of late-stage wins. The company reported positive data last month for mosliciguat in a high blood pressure condition linked to lung inflammation, a drug analysts think may exceed $10 billion in yearly sales¹. Roivant's model is to take later-stage medicines that larger pharma companies no longer want into dedicated “Vant” subsidiaries, and it has more than tripled its value over the past six years¹. Its record is mixed: failed Alzheimer's research in 2017 sank Axovant Sciences, one of its early units¹. For big pharma portfolio teams, the Pfizer deal is a live example of an out-licensed asset gaining value outside the originator.

Caveats

The results come from the company's announcement and have not yet been published in full, so detailed safety data and subgroup figures are not available in the report¹. Any advantage over Humira rests on cross-trial comparison rather than a head-to-head study¹. The next concrete step is Priovant's supplemental filing to the FDA, planned for the first half of next year¹.